| Bioactivity | CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds[1]. |
| Invitro | CAY10583 (1 nM-1μM; 24 hours) promotes wound closure via keratinocyte migration. And CAY10583 has no significant effect of on keratinocyte proliferation[1]. |
| In Vivo | CAY10583 (administered topically to full-thickness wounds; 10 μM; 14 days) significantly results in a greater wound closure than the control group. The difference in wound closure between the CAY-treated group and the control group is pronounced over time until day 10. And the difference is approximately 6% at day 4 and reaches almost 20% at day 8. Notably, 100% closure was observed in the CAY-treated group at day 14[1]. Animal Model: |
| Name | CAY10583 |
| CAS | 862891-27-8 |
| Formula | C25H25NO3 |
| Molar Mass | 387.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lin Luo, et al. A synthetic leukotriene B 4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes. J Diabetes Complications. 2017 Jan;31(1):1 |